کد مقاله | کد نشریه | سال انتشار | مقاله انگلیسی | نسخه تمام متن |
---|---|---|---|---|
4215490 | 1281136 | 2015 | 5 صفحه PDF | دانلود رایگان |
عنوان انگلیسی مقاله ISI
Ciblage de MET, T790M et ROS1
دانلود مقاله + سفارش ترجمه
دانلود مقاله ISI انگلیسی
رایگان برای ایرانیان
کلمات کلیدی
موضوعات مرتبط
علوم پزشکی و سلامت
پزشکی و دندانپزشکی
پزشکی ریوی و تنفسی
پیش نمایش صفحه اول مقاله

چکیده انگلیسی
In the last decade, the characterization of non-small-cell lung cancer into subtypes based on genotype has resulted in dramatic improvements in outcome in selected patient subgroups. Targeted agents that inhibit EGFR or ALK are approved for the treatment of NSCLC harboring genetic alterations of these genes. Similar to EGFR and ALK, those patients that harbor recently discovered molecular abnormalities such as ROS1 fusion or Met mutated or amplified were found to respond to targeted therapies. The most common mechanism of resistance to first-generation EGFR tyrosine kinase inhibitors is a new mutation T790M located in the exon 20 of EGFR. Encouraging results are observed with mutant-selective EGFR tyrosine kinase inhibitors, raising the possibility of overcoming drug resistance to erlotinib or gefitinib. This review provides an overview of the key developments in the treatment of NSCLC, and discusses potential strategies to further optimize therapy by targeting disease subtypes.
ناشر
Database: Elsevier - ScienceDirect (ساینس دایرکت)
Journal: Revue des Maladies Respiratoires Actualités - Volume 7, Issue 4, November 2015, Pages 506-510
Journal: Revue des Maladies Respiratoires Actualités - Volume 7, Issue 4, November 2015, Pages 506-510
نویسندگان
D. Moro-Sibilot, M. Duruisseaux, M. Giaj Levra, L. Sakhri, A.-C. Toffart,